Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Research outcomes and recommendations for the assessment of progression in cancer clinical trials.

Bushnell W, Stone A.

J Biopharm Stat. 2013;23(5):949-50. doi: 10.1080/10543406.2013.813718. No abstract available.

PMID:
23957508
[PubMed - indexed for MEDLINE]
2.
3.

Evaluation of discordance measures in oncology studies with blinded independent central review of progression-free survival using an observational error model.

Mannino FV, Amit O, Lahiri S.

J Biopharm Stat. 2013;23(5):971-85. doi: 10.1080/10543406.2013.813516.

PMID:
23957510
[PubMed - indexed for MEDLINE]
4.

Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.

Stone AM, Bushnell W, Denne J, Sargent DJ, Amit O, Chen C, Bailey-Iacona R, Helterbrand J, Williams G; PhRMA working group.

Eur J Cancer. 2011 Aug;47(12):1763-71. doi: 10.1016/j.ejca.2011.02.011. Epub 2011 Mar 22.

PMID:
21435858
[PubMed - indexed for MEDLINE]
5.

Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?

Saad ED, Buyse M.

J Clin Oncol. 2012 May 20;30(15):1750-4. doi: 10.1200/JCO.2011.38.6359. Epub 2012 Mar 5. No abstract available.

PMID:
22393092
[PubMed - indexed for MEDLINE]
6.

Critical evaluation of disease stabilization as a measure of activity of systemic therapy: lessons from trials with arms in which patients do not receive active treatment.

Le Tourneau C, Paoletti X, Coquan E, Sablin MP, Zoubir M, Tannock IF.

J Clin Oncol. 2014 Jan 20;32(3):260-3. doi: 10.1200/JCO.2013.53.5518. Epub 2013 Dec 2. No abstract available.

PMID:
24297942
[PubMed - indexed for MEDLINE]
7.

Criticism of tumor response criteria raises trial design questions.

Twombly R.

J Natl Cancer Inst. 2006 Feb 15;98(4):232-4. No abstract available.

PMID:
16478740
[PubMed - indexed for MEDLINE]
Free Article
8.

When progressive disease does not mean treatment failure: reconsidering the criteria for progression.

Oxnard GR, Morris MJ, Hodi FS, Baker LH, Kris MG, Venook AP, Schwartz LH.

J Natl Cancer Inst. 2012 Oct 17;104(20):1534-41. doi: 10.1093/jnci/djs353. Epub 2012 Aug 27.

PMID:
22927506
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Missing data and censoring in the analysis of progression-free survival in oncology clinical trials.

Denne JS, Stone AM, Bailey-Iacona R, Chen TT.

J Biopharm Stat. 2013;23(5):951-70. doi: 10.1080/10543406.2013.813515.

PMID:
23957509
[PubMed - indexed for MEDLINE]
10.

Clinical trials data collection: when less is more.

Sargent DJ, George SL.

J Clin Oncol. 2010 Dec 1;28(34):5019-21. doi: 10.1200/JCO.2010.31.7024. Epub 2010 Oct 4. No abstract available.

PMID:
20921455
[PubMed - indexed for MEDLINE]
11.

Progression-free survival remains debatable endpoint in cancer trials.

Tuma R.

J Natl Cancer Inst. 2009 Nov 4;101(21):1439-41. doi: 10.1093/jnci/djp399. Epub 2009 Oct 14. No abstract available.

PMID:
19828873
[PubMed - indexed for MEDLINE]
Free Article
12.

Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?

Pignatti F, Hemmings R, Jonsson B.

Eur J Cancer. 2011 Aug;47(12):1759-62. doi: 10.1016/j.ejca.2011.05.009. No abstract available.

PMID:
21641204
[PubMed - indexed for MEDLINE]
13.

Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.

Sobrero A, Bruzzi P.

J Clin Oncol. 2009 Dec 10;27(35):5868-73. doi: 10.1200/JCO.2009.22.4162. Epub 2009 Oct 13. No abstract available.

PMID:
19826122
[PubMed - indexed for MEDLINE]
14.

Clinical trial methods to discover and validate predictive markers for treatment response in cancer.

Paik S.

Biotechnol Annu Rev. 2003;9:259-67. Review.

PMID:
14650930
[PubMed - indexed for MEDLINE]
15.

Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease.

Pocard M, Soria JC, Aldaz-Carroll L, Bellet D.

J Clin Oncol. 2010 Oct 20;28(30):4551-3. doi: 10.1200/JCO.2010.29.2870. Epub 2010 Sep 13. No abstract available.

PMID:
20837954
[PubMed - indexed for MEDLINE]
16.

Trend toward noninferiority trials may mean more difficult interpretation of trial results.

Tuma RS.

J Natl Cancer Inst. 2007 Dec 5;99(23):1746-8. Epub 2007 Nov 27. No abstract available.

PMID:
18042926
[PubMed - indexed for MEDLINE]
Free Article
17.

NCI's cancer therapy evaluation program: a commitment to treatment trials.

Abrams JS, Murgo A, Christian MC.

Cancer Treat Res. 2007;132:31-50. Review. No abstract available.

PMID:
17305016
[PubMed - indexed for MEDLINE]
18.

Clinical cancer research 2001: new agents and therapies.

Verweij J, de Vries EG.

Drug Resist Updat. 2001 Aug;4(4):217-23. Review. No abstract available.

PMID:
11991676
[PubMed - indexed for MEDLINE]
19.

Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.

Arteaga CL, Baselga J.

Clin Cancer Res. 2003 May;9(5):1579-89. Review. No abstract available.

PMID:
12738709
[PubMed - indexed for MEDLINE]
Free Article
20.

Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?

Gehan EA, Tefft MC.

J Natl Cancer Inst. 2000 Feb 2;92(3):179-81. No abstract available.

PMID:
10655425
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk